

**产品名称: Bafetinib(INNO-406)**  
**产品别名: Bafetinib; 巴氟替尼; NS-187**

<b>生物活性:</b>																												
Description	Bafetinib is a Lyn and Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity.																											
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : <math>\geq</math> 42 mg/mL (72.84 mM)</p> <p>* "<math>\geq</math>" means soluble, but saturation unknown.</p>																											
	<p><b>Preparing Stock Solutions</b></p> <table border="1"> <thead> <tr> <th>Solvent</th> <th>Mass</th> <th>Concentration</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>1.7342 mL</td> <td></td> <td>8.6712 mL</td> <td>17.3424 mL</td> <td></td> </tr> <tr> <td>5 mM</td> <td>0.3468 mL</td> <td></td> <td>1.7342 mL</td> <td>3.4685 mL</td> <td></td> </tr> <tr> <td>10 mM</td> <td>0.1734 mL</td> <td></td> <td>0.8671 mL</td> <td>1.7342 mL</td> <td></td> </tr> </tbody> </table>	Solvent	Mass	Concentration	1 mg	5 mg	10 mg	1 mM	1.7342 mL		8.6712 mL	17.3424 mL		5 mM	0.3468 mL		1.7342 mL	3.4685 mL		10 mM	0.1734 mL		0.8671 mL	1.7342 mL		1 mM	1.7342 mL	8.6712 mL
Solvent	Mass	Concentration	1 mg	5 mg	10 mg																							
1 mM	1.7342 mL		8.6712 mL	17.3424 mL																								
5 mM	0.3468 mL		1.7342 mL	3.4685 mL																								
10 mM	0.1734 mL		0.8671 mL	1.7342 mL																								
5 mM	0.3468 mL	1.7342 mL	3.4685 mL																									
10 mM	0.1734 mL	0.8671 mL	1.7342 mL																									
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p>																												
<b>References</b>	<p>[1]. Grace MS, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol. 2014 Aug;171(16):3881-3894.</p> <p>[2]. Kimura S, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005 Dec 1;106(12):3948-3954.</p> <p>[3]. Kamitsui Y, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008, 15(11), 1712-2172.</p> <p>[4]. Yokota A, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007, 109(1), 306-314.</p>																											

# 源叶生物